LL-37 (17-29) [18SA-K] [K25L]

General Information


DRACP ID  DRACP02871

Peptide Name   LL-37 (17-29) [18SA-K] [K25L]

Sequence  FXRIVQRILDFLR

Sequence Length  13

UniProt ID  P49913 

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
A549 Lung adenocarcinoma Carcinoma IC50=10.7 μg/ml MTT assay 24 h 1

Hemolytic Activity  Human erythrocytes: Not active up to 500 µg/ml

Normal (non-cancerous) Cytotoxicity  DLF lung fibroblasts: IC50=24.3 μg/ml

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial; Antifungal



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Acetylation

C-terminal Modification  Amidation

Other Modification  X=Sialic acid-Lys

Chiral  L



Physicochemical Information


Formula  C74H120N22O15

Absent amino acids  ACEGHKMNPSTWY

Common amino acids  R

Mass  188213

Pl  12.2

Basic residues  3

Acidic residues  1

Hydrophobic residues  7

Net charge  2

Boman Index  -2934

Hydrophobicity  45.38

Aliphatic Index  142.31

Half Life 
  /

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 32567085

Title  Cationic amphipathic peptide analogs of cathelicidin LL-37 as a probe in the development of antimicrobial/anticancer agents

Doi 10.1002/psc.3254

Year  2020

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.